Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 13, 2025The Journal of Clinical PharmacologyOpen Access

Post‐Marketing Safety Assessment for Glucagon‐Like Peptide‐1 and Dual Incretin Therapies in Diabetes and Obesity

View Full Paper
Ask AI
Bookmark
Share

Authors

CWChien‐Hsiang WengCBCharles L. BennettJMJoseph Magagnoli

Discussion

Loading...

Member takes

Overview

Observational analysis highlights potential adverse drug reactions in patients receiving GLP-1RAs and tirzepatide, indicating a need for careful pharmacovigilance.

Key Points

  • Accurate interpretation of potential adverse drug reactions is essential for clinicians to counsel patients effectively.
  • Pharmacovigilance efforts show significant disparities in reporting practices between healthcare professionals and patients.
  • Tirzepatide's unique mechanism may lead to different side effects, underscoring the need for drug-specific analyses.
  • Long-term post-marketing surveillance is crucial to identify rare adverse events associated with newer therapies.

Cite This Study

Weng et al. (2025) studied this question.

synapsesocial.com/papers/68ec51df42911f61ef8b20eehttps://doi.org/10.1002/jcph.70119
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Postmarketing Safety Signals and Medication‐Use Risks of GLP ‐1‐Based Therapies in Diabetes and Obesity: A Multi‐Source Pharmacovigilance and Regulatory Evidence‐Mapping Study2026
  2. 2Integrated Evidence from VigiBase and Clinical Trials: A Comprehensive Pharmacovigilance Analysis of Seven Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs)2026
  3. 3Incretin-Based Drugs for Obesity: Common and Drug-Specific Reporting Patterns of Adverse Drug Reactions—A Comparative Disproportionality Analysis Using EudraVigilance Reports Integrating SmPC Data2026 · 3 citations
  4. 4A Pharmacovigilance Analysis of Ocular Adverse Events Associated with GLP-1 Receptor Agonists2026 · 2 citations
  5. 5Evaluation of the safety profile of glucagon-like peptide-1 receptor agonists: a focus on thyroid cancer-related adverse events by using the European pharmacovigilance database2026